Management of hospitalized patients with pulmonary arterial hypertension and COVID-19 infection

The novel coronavirus SARS-CoV2 that causes coronavirus disease 2019 (COVID-19), has approximately afflicted over 2 million people worldwide,1 including approximately a million cases with over 50,000 deaths in the United States2 as of 27 April 2020. Pulmonary arterial hypertension (PAH), a chronic, progressively fatal condition, requires complicated medical management.3 Patients with PAH are very sensitive to the changes in their cardiopulmonary status and any disruption in treatment or development of additional cardiac or pulmonary pathology can trigger a rapid course of decline leading to death. Furthermore, all-cause hospitalization itself is a risk factor for disease progression in PAH.4 A recently published small case series suggested that 86% of critically ill COVID-19-infected patients had heart failure and chronic kidney disease as the most common underlying medical conditions.5 These conditions are commonly seen in patients with PAH and increase the risk for PAH patients to develop severe disease. Many PAH patients are on complicated regimens, including oral, inhaled or continuous intravenous therapies, some of which may be difficult to deliver during an acute illness. In this brief communication, we will highlight the in-patient management of COVID-19-infected PAH patients.

 

Read the full article online

Topics

Pulmonary Arterial Hypertension
Pulmonary Hypertension

Authors

Sandeep Sahay, Harrison W. Farber

Published in:

Pulmonary Circulation Vol 10: No 3 cover image

July 2020

Pulmonary Circulation Vol 10: No 3

View this journal

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI
standard-example-image.jpg